Last reviewed · How we verify
TNX-201 35 mg
TNX-201 35 mg is a Small molecule drug developed by Tonix Pharmaceuticals, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | TNX-201 35 mg |
|---|---|
| Sponsor | Tonix Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache (PHASE2)
- Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNX-201 35 mg CI brief — competitive landscape report
- TNX-201 35 mg updates RSS · CI watch RSS
- Tonix Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about TNX-201 35 mg
What is TNX-201 35 mg?
TNX-201 35 mg is a Small molecule drug developed by Tonix Pharmaceuticals, Inc..
Who makes TNX-201 35 mg?
TNX-201 35 mg is developed by Tonix Pharmaceuticals, Inc. (see full Tonix Pharmaceuticals, Inc. pipeline at /company/tonix-pharmaceuticals-inc).
What development phase is TNX-201 35 mg in?
TNX-201 35 mg is in Phase 1.
Related
- Manufacturer: Tonix Pharmaceuticals, Inc. — full pipeline
- Compare: TNX-201 35 mg vs similar drugs
- Pricing: TNX-201 35 mg cost, discount & access